Treatments for foot drop compared
The study in brief
Foot drop can be treated using two types of device. Functional electrical stimulation (FES) uses small electrical charges to the muscles of the lower leg to force the foot into a more natural position for walking. An ankle-foot orthosis (AFO) is a device made of plastic or carbon fibre that holds the foot and ankle in a correct position to prevent the foot from dropping down during walking.
There’s been very little research comparing the two devices, so this study aimed to compare the effectiveness and relative costs of AFO and FES in people with MS.
Seventy nine people were recruited from seven centres in Scotland and randomly assigned to be fitted with an AFO or an FES. The impact of the device was measured at the start, 3, 6 and 12 months.
The relatively small number of participants and the high drop out rate (38%) made it difficult to draw firm conclusions from the study. Both groups walked faster when wearing their devices at 12 months, with neither of the devices showing a clear advantage over the other. There was no evidence that either device had a therapeutic effect, that is, improved unassisted walking performance. Overall, results suggested that AFO devices were less acceptable to people with MS; the researchers conclude that both the physical and psychological impact of a device needs to be taken into account as both these contribute to someone’s willingness to keep using a device.
The study in more detail
Background
Foot drop is a symptom experienced by some people with multiple sclerosis. It is caused by a disruption in the nerve pathway to and from the brain, which makes it difficult to lift the foot and toes properly when walking. As a result, your foot tends to catch or drag along the ground, increasing the risk of tripping or falling. People often change their walking style to compensate for this, leading to extra wear on joints and increasing the effort of walking.
Foot drop can be treated using two types of device. Functional electrical stimulation (FES) uses small electrical charges to the muscles of the lower leg to force the foot into a more natural position for walking. An ankle-foot orthosis (AFO) is a device made of plastic or carbon fibre that holds the foot and ankle in a correct position to prevent the foot from dropping down during walking.
There’s been very little research comparing the two devices, so this study aimed to compare the effectiveness and relative costs of AFO and FES in people with MS.
How this study was carried out
The researchers recruited 79 people with foot drop caused by MS from seven centres in Scotland. Participants were excluded if they had previously used either of the devices. Participants were randomly assigned to be fitted with a custom-made AFO or with an FES. They were instructed to gradually increase the wear of their devices over the first 6 weeks.
The impact of the device on walking was measured at the start, 3, 6, and 12 months. The main measure of the study was walking speed, calculated from the distance walked in five minutes at the person’s preferred pace. Additional measures included the amount of oxygen taken up while walking and the time taken to walk 25 feet. Participants also completed questionnaires to measure the impact of MS and the device on symptoms, quality of life, independence and well-being.
What was found?
Both groups walked faster when wearing their devices at 12 months, with neither of the devices showing greater improvement than the other. None of the other measures showed a clear, consistent advantage of one device over the other. There was no evidence from the study that either device had a therapeutic effect ie resulted in an improvement in unassisted walking.
Over the 12 months, 37 people (38%) dropped out of the study for a variety of reasons. Although there was no statistically significant difference between the groups, the proportion of drop outs was higher in the AFO group, and most of these because they were unhappy with the device.
The FES group gave significantly higher scores for a questionnaire which assessed the impact of wearing a device on quality of life and sense of well-being (Psychological Impact of Assistive Devices Scale). This indicated that FES was more acceptable to wearers than AFO.
What does it mean?
The relatively small number of participants completing the study (22 of 43 AFO, 31 of 42 FES) means it is difficult to draw definite conclusions. Overall, both types of device improved walking speed, although neither device appeared to improve unassisted walking.
For some people, assistive devices can be viewed as a symbol of disability, a loss of independence and altered self-image. Some participants in the AFO group reported that wearing their device emphasised their disability and this may have contributed to the higher drop out rate seen in this group, reflected in the lower scores for the psychological impact questionnaire. The researchers acknowledged that the lower acceptance of the AFO devices may have been caused, at least in part, by the rigid design of the orthosis that was used as a standard across the seven centres; allowing physiotherapists to prescribe an orthosis more suitable for individual participants might have improved acceptance. However, the researchers point out that both the physical and psychological impact of a device need to be taken into account in clinical studies as both these are important factors for continued use of the device.
The researchers conclude that despite higher initial costs of FES, it offers value for money as an alternative to the more routinely used ankle-foot orthoses.
Renfrew LM, Paul L, McFadyen A, et al.
The clinical- and cost-effectiveness of functional electrical stimulation and ankle-foot orthoses for foot drop in multiple sclerosis: a multicentre randomized trial.
Clin Rehabil. 2019 Apr 11:269215519842254.
Summary
More about walking problems, orthoses and functional electrical stimulation
Many people with MS have some difficulties with walking but walking problems vary considerably from one person with MS to another. Common difficulties include: unsteadiness on walking or turning, tripping, stumbling, weakness of the leg when weight is on it and difficulty placing the foot on the ground. Other MS symptoms can also make walking more difficult, such as vision problems, balance problems and pain. Having trouble walking can mean people with MS are more vulnerable to tripping and falling. It can also use up more energy, making fatigue worse, and people may alter how they walk to try and compensate for the difficulty they are having. This alteration in walking can result in bad posture which can lead to pain and strains.
If you are experiencing walking difficulties, you can speak to your MS nurse or GP who may refer you to physiotherapy services. The best way forward depends on what is causing the difficulties. Treatment may involve physiotherapy or drug treatments to alleviate specific underlying symptoms such as spasticity or pain.
Find out more about walking problems, foot drop, functional electrical stimulationand orthoses.
Browse more from the latest research
Causes of MS
Nourbakhsh B, Mowry EM.
Multiple sclerosis risk factors and pathogenesis.
Continuum (Minneap Minn). 2019 Jun;25(3):596-610. doi: 10.1212/CON.0000000000000725.
Summary(link is external)
Dalla Costa G, Romeo M, Esposito F, Sangalli F, Colombo B, Radaelli M, Moiola L, Comi G, Martinelli V.
Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis.
Mult Scler Relat Disord. 2019 May 21;33:75-77. doi: 10.1016/j.msard.2019.05.010. [Epub ahead of print]
Summary(link is external)
CCSVI
Jagannath VA, Pucci E, Asokan GV, Robak EW.
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis.
Cochrane Database Syst Rev. 2019 May 31;5:CD009903. doi: 10.1002/14651858.CD009903.pub3.
Summary(link is external)
Read the full text of this paper (link is external)
Childhood MS
Galardi MM, Gaudioso C, Ahmadi S, Evans E, Gilbert L, Mar S.
Differential diagnosis of pediatric multiple sclerosis.
Children (Basel). 2019 Jun 3;6(6). pii: E75. doi: 10.3390/children6060075. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Rensel M.
Long-term treatment strategies of pediatric multiple sclerosis, including the use of disease modifying therapies.
Children (Basel). 2019 May 31;6(6). pii: E73. doi: 10.3390/children6060073. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Wilbur C, Yeh EA.
Improving outcomes in pediatric multiple sclerosis: current and emerging treatments.
Paediatr Drugs. 2019 Jun;21(3):137-152. doi: 10.1007/s40272-019-00338-6.
Summary(link is external)
McKay KA, Hillert J, Manouchehrinia A.
Long-term disability progression of pediatric-onset multiple sclerosis.
Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.
Summary(link is external)
Read the full text of this paper (link is external)
Kopp TI, Blinkenberg M, Chalmer TA, Petersen T, Ravnborg MH, Soelberg Sørensen P, Magyari M.
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100. [Epub ahead of print]
Summary(link is external)
Co-existing conditions
Quinlan ND, Chen DQ, Werner BC, Barnes CL, Browne JA.
Patients with multiple sclerosis are at increased risk for postoperative complications following total hip and knee arthroplasty.
J Arthroplasty. 2019 Apr 12. pii: S0883-5403(19)30354-7. doi: 10.1016/j.arth.2019.04.022. [Epub ahead of print]
Summary(link is external)
Diagnosis
Solomon AJ.
Diagnosis, differential diagnosis, and misdiagnosis of Multiple Sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):611-635. doi: 10.1212/CON.0000000000000728.
Summary(link is external)
Zipp F, Oh J, Fragoso YD, Waubant E.
Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis.
Nat Rev Neurol. 2019 May 13. doi: 10.1038/s41582-019-0194-0. [Epub ahead of print] Review.
Summary(link is external)
Steenhof M, Stenager E, Nielsen NM, Kyvik K, Möller S, Hertz JM.
Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases.
Mult Scler Relat Disord. 2019 Jul;32:97-102. doi: 10.1016/j.msard.2019.04.012. Epub 2019 Apr 13.
Summary(link is external)
Disease modifying drugs
Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
BMC Neurol. 2019 Jun 8;19(1):116. doi: 10.1186/s12883-019-1337-z.
Summary(link is external)
Read the full text of this paper (link is external)
Scarpazza C, De Rossi N, Tabiadon G, Turrini MV, Gerevini S, Capra R.
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
Neurol Sci. 2019 Jun 7. doi: 10.1007/s10072-019-03959-4. [Epub ahead of print]
Summary(link is external)
Dekker I, Leurs CE, Hagens MHJ, van Kempen ZLE, Kleerekooper I, Lissenberg-Witte BI, Barkhof F, Uitdehaag BMJ, Balk LJ, Wattjes MP, Killestein J.
Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Mult Scler Relat Disord. 2019 May 28;33:82-87. doi: 10.1016/j.msard.2019.05.017. [Epub ahead of print]
Summary(link is external)
Gross RH, Corboy JR.
Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies.
Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738.
Summary(link is external)
Bartolomé-García E, Usarralde-Pérez Á, Sanmartín-Fenollera P, Pérez-Encinas M.
Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis.
Eur J Hosp Pharm Sci Pract. 2019 Jan;26(1):23-28. doi: 10.1136/ejhpharm-2017-001286. Epub 2017 Aug 31.
Summary(link is external)
Fragoso YD, Adoni T, Gomes S, Goncalves MVM, Parolin LF, Rosa G, Ruocco HH.
Severe exacerbation of multiple sclerosis following withdrawal of fingolimod.
Clin Drug Investig. 2019 May 31. doi: 10.1007/s40261-019-00804-6. [Epub ahead of print]
Summary(link is external)
Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F.
Treatment of natalizumab-associated PML with filgrastim.
Ann Clin Transl Neurol. 2019 Apr 8;6(5):923-931. doi: 10.1002/acn3.776. eCollection 2019 May.
Summary(link is external)
Read the full text of this paper (link is external)
Buesa-Estelléz A, Cano-de-la-Cuerda R, Ortiz-Gutiérrez RM, Palacios-Ceña D.
The impact of pharmacological treatment on patients with multiple sclerosis.
Disabil Health J. 2019 May 21. pii: S1936-6574(19)30098-6. doi: 10.1016/j.dhjo.2019.05.005. [Epub ahead of print]
Summary(link is external)
Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S.
Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Mult Scler Relat Disord. 2019 May 9;33:13-21. doi: 10.1016/j.msard.2019.04.036. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Li H, Hu F, Zhang Y, Li K.
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
J Neurol. 2019 May 25. doi: 10.1007/s00415-019-09395-w. [Epub ahead of print] Review.
Summary(link is external)
Fiander MDJ, Bhan V, Stewart SA, Parks NE.
Clinical course of relapsing remitting multiple sclerosis post-natalizumab.
Can J Neurol Sci. 2019 Jul;46(4):455-458. doi: 10.1017/cjn.2019.42. Epub 2019 May 22.
Summary(link is external)
Schmidt S, Schulten T.
Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases.
Ther Adv Neurol Disord. 2019 May 6;12:1756286419846818. doi: 10.1177/1756286419846818. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Briner M, Bagnoud M, Miclea A, Friedli C, Diem L, Chan A, Hoepner R, Salmen A.
Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age.
Ther Adv Neurol Disord. 2019 May 8;12:1756286419843450. doi: 10.1177/1756286419843450. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Scott LJ.
Teriflunomide: a review in relapsing-remitting multiple sclerosis.
Drugs. 2019 Jun;79(8):875-886. doi: 10.1007/s40265-019-01135-8.
Summary(link is external)
De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C.
Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.
Expert Rev Neurother. 2019 May;19(5):417-429. doi: 10.1080/14737175.2019.1610393. Epub 2019 May 16.
Summary(link is external)
Drugs in development
Negron A, Robinson RR, Stüve O, Forsthuber TG.
The role of B cells in multiple sclerosis: Current and future therapies.
Cell Immunol. 2019 May;339:10-23. doi: 10.1016/j.cellimm.2018.10.006. Epub 2018 Oct 21.
Summary(link is external)
Read the full text of this paper (link is external)
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group..
Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis.
N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10.
Summary(link is external)
Moss BP, Cohen JA.
The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106. [Epub ahead of print]
Summary(link is external)
Economics
García-Domínguez JM, Maurino J, Martínez-Ginés ML, Carmona O, Caminero AB, Medrano N, Ruíz-Beato E; W-IMPACT Clinical Investigators..
Economic burden of multiple sclerosis in a population with low physical disability.
BMC Public Health. 2019 May 20;19(1):609. doi: 10.1186/s12889-019-6907-x. Erratum in: BMC Public Health. 2019 Jul 8;19(1):909.
Summary(link is external)
Read the full text of this paper (link is external)
Epidemiology
Söderholm J, Yilmaz A, Svenningsson A, Büsch K, Wejstål R, Brolund A, Kövamees J, Sällberg M, Lagging M, Gisslén M.
Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.
J Neurol. 2019 May 31. doi: 10.1007/s00415-019-09397-8. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
McDonald JJ, Weller B, O'Neil M, Waters C, O'Riordan J; Scottish MS Register Study Collaborators..
Latitudinal variation in MS incidence in Scotland.
Mult Scler Relat Disord. 2019 Jul;32:116-122. doi: 10.1016/j.msard.2019.04.032. Epub 2019 Apr 30.
Summary(link is external)
Munk Nielsen N, Corn G, Frisch M, Stenager E, Koch-Henriksen N, Wohlfahrt J, Magyari M, Melbye M.
Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study.
Brain. 2019 Jun 1;142(6):1587-1597. doi: 10.1093/brain/awz088.
Summary(link is external)
Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836. [Epub ahead of print]
Summary(link is external)
Families
Wawrziczny E, Corrairie A, Antoine P.
Relapsing-remitting multiple sclerosis: an interpretative phenomenological analysis of dyadic dynamics.
Disabil Rehabil. 2019 May 26:1-9. doi: 10.1080/09638288.2019.1617794. [Epub ahead of print]
Summary(link is external)
Herbert LB, Zerkowski K, O'Brien S, Leonard KV, Bhowmick A.
Impact on interpersonal relationships among patients with multiple sclerosis and their partners.
Neurodegener Dis Manag. 2019 Jun;9(3):173-187. doi: 10.2217/nmt-2018-0045. Epub 2019 May 22.
Summary(link is external)
Read the full text of this paper (link is external)
Other treatments
Helis CA, McTyre E, Munley MT, Bourland JD, Lucas JT, Cramer CK, Tatter SB, Laxton AW, Chan MD.
Gamma knife radiosurgery for multiple sclerosis-associated trigeminal neuralgia.
Neurosurgery. 2019 Jun 7. pii: nyz182. doi: 10.1093/neuros/nyz182. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Daly L, Gibson CE, Dewing J.
Caring for people with multiple sclerosis who use cannabis for symptom control.
Br J Community Nurs. 2019 Jun 2;24(6):257. doi: 10.12968/bjcn.2019.24.6.265.
Summary(link is external)
Lebrun C, Vukusic S; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP)..
Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society.
Mult Scler Relat Disord. 2019 Jun;31:173-188. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10. Review.
Summary(link is external)
Marzal-Alfaro MB, Martín Barbero ML, García Domínguez J, Romero-Delgado F, Martínez Ginés ML, Herranz A, Sanjurjo-Sáez M.
Impact of fampridine on quality of life: clinical benefit in real-world practice.
Eur J Hosp Pharm Sci Pract. 2018 May;25(3):138-143. doi: 10.1136/ejhpharm-2016-001129. Epub 2017 Jan 13.
Summary(link is external)
Read the full text of this paper (link is external)
Gustavsen S, Søndergaard HB, Andresen SR, Magyari M, Sørensen PS, Sellebjerg F, Oturai AB.
Illegal cannabis use is common among Danes with multiple sclerosis.
Mult Scler Relat Disord. 2019 May 16;33:5-12. doi: 10.1016/j.msard.2019.05.008. [Epub ahead of print]
Summary(link is external)
Benlloch M, López-Rodríguez MM, Cuerda-Ballester M, Drehmer E, Carrera S, Ceron JJ, Tvarijonaviciute A, Chirivella J, Fernández-García D, de la Rubia Ortí JE.
Satiating effect of a ketogenic diet and its impact on muscle improvement and oxidation state in multiple sclerosis patients.
Nutrients. 2019 May 23;11(5). pii: E1156. doi: 10.3390/nu11051156.
Summary(link is external)
Read the full text of this paper (link is external)
Jakimovski D, Guan Y, Ramanathan M, Weinstock-Guttman B, Zivadinov R.
Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings.
Neurodegener Dis Manag. 2019 Jun;9(3):149-172. doi: 10.2217/nmt-2018-0046. Epub 2019 May 22.
Summary(link is external)
Probst Y, Mowbray E, Svensen E, Thompson K.
A systematic review of the impact of dietary sodium on autoimmunity and inflammation related to multiple sclerosis.
Adv Nutr. 2019 May 11. pii: nmz032. doi: 10.1093/advances/nmz032. [Epub ahead of print]
Summary(link is external)
Abbasi M, Kordi Yoosefinejad A, Poursadeghfard M, Parsaei Jahromi F, Motealleh A, Sobhani S.
Whole body vibration improves core muscle strength and endurance in ambulant individuals with multiple sclerosis: A randomized clinical trial.
Mult Scler Relat Disord. 2019 Jul;32:88-93. doi: 10.1016/j.msard.2019.04.028. Epub 2019 Apr 30.
Summary(link is external)
Pregnancy
Langer-Gould AM.
Pregnancy and family planning in multiple sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745.
Summary(link is external)
Moberg JY, Laursen B, Thygesen LC, Magyari M.
Reproductive history of the Danish multiple sclerosis population: A register-based study.
Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245. [Epub ahead of print]
Summary(link is external)
Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, et al.
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.
Summary(link is external)
Prognosis
Ontaneda D.
Progressive multiple sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):736-752. doi: 10.1212/CON.0000000000000727.
Summary(link is external)
Bowen JD.
Highly aggressive multiple sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):689-714. doi: 10.1212/CON.0000000000000731.
Summary(link is external)
Metz LM.
Clinically isolated syndrome and early relapsing multiple sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):670-688. doi: 10.1212/CON.0000000000000729.
Summary(link is external)
Kantarci OH.
Phases and phenotypes of multiple sclerosis.
Continuum (Minneap Minn). 2019 Jun;25(3):636-654. doi: 10.1212/CON.0000000000000737.
Summary(link is external)
Ozakbas S, Cinar BP, Kahraman T; Multiple Sclerosis Research Group..
The 20-year history: Change of multiple sclerosis patient profile over 20 years.
Mult Scler Relat Disord. 2019 May 16;33:1-4. doi: 10.1016/j.msard.2019.05.002. [Epub ahead of print]
Summary(link is external)
Downer MB, Wallack EM, Ploughman M; Health, Lifestyle, and Aging with MS Canadian Consortium..
Octogenarians with multiple sclerosis: lessons for aging in place.
Can J Aging. 2019 May 14:1-10. doi: 10.1017/S0714980819000163. [Epub ahead of print]
Summary(link is external)
Provision of care
Falet JR, Deshmukh S, Al-Jassim A, Sigler G, Babinski M, Moore F.
The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107. [Epub ahead of print]
Summary(link is external)
Psychological aspects
Klineova S, Brandstadter R, Fabian MT, Sand IK, Krieger S, Leavitt VM, Lewis C, Riley CS, Lublin F, Miller AE, Sumowski JF.
Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725. [Epub ahead of print]
Summary(link is external)
Genova HM, Lancaster K, Lengenfelder J, Bober CP, DeLuca J, Chiaravalloti ND.
Relationship between social cognition and fatigue, depressive symptoms, and anxiety in multiple sclerosis.
J Neuropsychol. 2019 Jun 1. doi: 10.1111/jnp.12185. [Epub ahead of print]
Summary(link is external)
Eldridge-Smith ED, Loew M, Stepleman LM.
The adaptation and validation of a stigma measure for individuals with multiple sclerosis.
Disabil Rehabil. 2019 May 25:1-8. doi: 10.1080/09638288.2019.1617793. [Epub ahead of print]
Summary(link is external)
Rehabilitation
Sadeghi Bahmani D, Kesselring J, Papadimitriou M, Bansi J, Pühse U, Gerber M, Shaygannejad V, Holsboer-Trachsler E, Brand S.
In patients with multiple sclerosis, both objective and subjective sleep, depression, fatigue, and paresthesia improved after 3 weeks of regular exercise.
Front Psychiatry. 2019 May 3;10:265. doi: 10.3389/fpsyt.2019.00265. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Turner AP, Hartoonian N, Hughes AJ, Arewasikporn A, Alschuler KN, Sloan AP, Ehde DM, Haselkorn JK.
Physical activity and depression in MS: The mediating role of behavioral activation.
Disabil Health J. 2019 Apr 30. pii: S1936-6574(19)30063-9. doi: 10.1016/j.dhjo.2019.04.004. [Epub ahead of print]
Summary(link is external)
Mayo CD, Miksche K, Attwell-Pope K, Gawryluk JR.
The relationship between physical activity and symptoms of fatigue, mood, and perceived cognitive impairment in adults with multiple sclerosis.
J Clin Exp Neuropsychol. 2019 Sep;41(7):715-722. doi: 10.1080/13803395.2019.1614535. Epub 2019 May 16.
Summary(link is external)
Jeng B, Sasaki JE, Cederberg KL, Motl RW.
Sociodemographic and clinical correlates of device-measured sedentary behaviour in multiple sclerosis.
Disabil Rehabil. 2019 May 16:1-7. doi: 10.1080/09638288.2019.1614683. [Epub ahead of print]
Summary(link is external)
Bonzano L, Pedullà L, Tacchino A, Brichetto G, Battaglia MA, Mancardi GL, Bove M.
Upper limb motor training based on task-oriented exercises induces functional brain reorganization in patients with multiple sclerosis.
Neuroscience. 2019 Jul 1;410:150-159. doi: 10.1016/j.neuroscience.2019.05.004. Epub 2019 May 11.
Summary(link is external)
Meyer C, Killeen T, Lörincz L, Curt A, Bolliger M, Linnebank M, Zörner B, Filli L.
Repeated assessment of key clinical walking measures can induce confounding practice effects.
Mult Scler. 2019 May 13:1352458519845839. doi: 10.1177/1352458519845839. [Epub ahead of print]
Summary(link is external)
Moumdjian L, Moens B, Maes PJ, Van Nieuwenhoven J, Van Wijmeersch B, Leman M, Feys P.
Walking to music and metronome at various tempi in persons with multiple sclerosis: a basis for rehabilitation.
Neurorehabil Neural Repair. 2019 Jun;33(6):464-475. doi: 10.1177/1545968319847962. Epub 2019 May 13.
Summary(link is external)
Relapses
Repovic P.
Management of multiple sclerosis relapses.
Continuum (Minneap Minn). 2019 Jun;25(3):655-669. doi: 10.1212/CON.0000000000000739.
Summary(link is external)
Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L, Edan G, Kerbrat A.
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090. [Epub ahead of print]
Summary(link is external)
Symptoms and symptom management
Mascialino G, Gromisch ES, Zemon V, Foley FW.
Potential differences in cognition by race/ethnicity among persons with multiple sclerosis in a clinical setting: A preliminary study.
NeuroRehabilitation. 2019;44(3):445-449. doi: 10.3233/NRE-182654.
Summary(link is external)
Tobin WO.
Management of multiple sclerosis symptoms and comorbidities.
Continuum (Minneap Minn). 2019 Jun;25(3):753-772. doi: 10.1212/CON.0000000000000732.
Summary(link is external)
Cederberg KLJ, Jeng B, Sasaki JE, Braley TJ, Walters AS, Motl RW.
Restless legs syndrome and health-related quality of life in adults with multiple sclerosis.
J Sleep Res. 2019 Jun 3:e12880. doi: 10.1111/jsr.12880. [Epub ahead of print]
Summary(link is external)
Jakimovski D, Weinstock-Guttman B, Roy S, Jaworski M 3rd, Hancock L, Nizinski A, Srinivasan P, Fuchs TA, Szigeti K, Zivadinov R, Benedict RHB.
Cognitive profiles of aging in multiple sclerosis.
Front Aging Neurosci. 2019 May 10;11:105. doi: 10.3389/fnagi.2019.00105. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Gascoyne CR, Simpson S Jr, Chen J, van der Mei I, Marck CH.
Modifiable factors associated with depression and anxiety in multiple sclerosis.
Acta Neurol Scand. 2019 May 23. doi: 10.1111/ane.13132. [Epub ahead of print]
Summary(link is external)
Thomas S, Pulman A, Thomas P, Collard S, Jiang N, Dogan H, Davies Smith A, Hourihan S, Roberts F, Kersten P, Pretty K, Miller JK, Stanley K, Gay MC.
Digitizing a face-to-face group fatigue management program: exploring the views of people with multiple sclerosis and health care professionals via consultation groups and interviews.
JMIR Form Res. 2019 May 22;3(2):e10951. doi: 10.2196/10951.
Summary(link is external)
Read the full text of this paper (link is external)
Taveira FM, Braz NFT, Comini-Frota ER, Teixeira AL, Domingues RB.
Disability as a determinant of fatigue in MS patients.
Arq Neuropsiquiatr. 2019 May 13;77(4):248-253. doi: 10.1590/0004-282X20190035.
Summary(link is external)
Read the full text of this paper (link is external)
Newsome SD, von Geldern G, Shou H, Baynes M, Marasigan RER, Calabresi PA, Zackowski KM.
Longitudinal assessment of hand function in individuals with multiple sclerosis.
Mult Scler Relat Disord. 2019 Jul;32:107-113. doi: 10.1016/j.msard.2019.04.035. Epub 2019 May 6.
Summary(link is external)
Friedova L, Rusz J, Motyl J, Srpova B, Vodehnalova K, Andelova M, Novotna K, Novotny M, Ruzickova H, Tykalova T, Kubala Havrdova E, Horakova D, Uher T.
Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study.
J Clin Neurosci. 2019 Jul;65:28-33. doi: 10.1016/j.jocn.2019.04.018. Epub 2019 May 6.
Summary(link is external)
Langenbruch L, Krämer J, Güler S, Möddel G, Geßner S, Melzer N, Elger CE, Wiendl H, Budde T, Meuth SG, Kovac S.
Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.
J Neurol. 2019 Jul;266(7):1789-1795. doi: 10.1007/s00415-019-09332-x. Epub 2019 May 8.
Summary(link is external)
Vitamin D
Graves JS, Barcellos LF, Krupp L, Belman A, Shao X, Quach H, Hart J, Chitnis T, Weinstock-Guttman B, Aaen G, Benson L, Gorman M, Greenberg B, Lotze T, Soe M, Ness J, Rodriguez M, Rose J, Schreiner T, Tillema JM, Waldman A, Casper TC, et al.
Vitamin D genes influence MS relapses in children.
Mult Scler. 2019 May 13:1352458519845842. doi: 10.1177/1352458519845842. [Epub ahead of print]
Summary(link is external)


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.


Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.